Given the results of RADICALS/HD, RADICALS/RT trials, it seems as though there was no benefit to adding ST-ADT to RT, but a DFMS benefit for LT-ADT over ST-ADT.
I’m not sure I’m ready to routinely rx LT-ADT in all settings, especially in light of the other positive ST-ADT trials (GETUG, SPPORT) and known risks of LT-ADT (per 9601).